Maze Therapeutics (NASDAQ:MAZE) Hits New 1-Year Low – What’s Next?

Maze Therapeutics, Inc. (NASDAQ:MAZE)’s stock price hit a new 52-week low on Friday . The company traded as low as $22.44 and last traded at $22.2150, with a volume of 78037 shares. The stock had previously closed at $23.44.

Analyst Upgrades and Downgrades

MAZE has been the subject of a number of analyst reports. TD Cowen raised shares of Maze Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Wall Street Zen lowered Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. Finally, BTIG Research restated a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a report on Wednesday, August 12th. Three analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $66.00.

Maze Therapeutics Trading Down 5.3%

The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 18.31. The company has a market capitalization of $1.23 billion, a price-to-earnings ratio of -8.81 and a beta of 2.17. The business has a fifty day moving average price of $27.53 and a 200 day moving average price of $29.74.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, meeting analysts’ consensus estimates of ($0.76). On average, equities analysts expect that Maze Therapeutics, Inc. will post -2.72 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Jason Coloma sold 11,411 shares of the company’s stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $26.01, for a total value of $296,800.11. Following the sale, the chief executive officer owned 27,362 shares of the company’s stock, valued at approximately $711,685.62. This represents a 29.43% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Atul Dandekar sold 3,243 shares of the company’s stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $26.01, for a total transaction of $84,350.43. Following the sale, the insider directly owned 32,316 shares in the company, valued at $840,539.16. This represents a 9.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 219,317 shares of company stock valued at $5,989,040. 5.30% of the stock is currently owned by insiders.

Institutional Trading of Maze Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Squarepoint Ops LLC lifted its stake in Maze Therapeutics by 42.8% in the second quarter. Squarepoint Ops LLC now owns 19,434 shares of the company’s stock valued at $580,000 after buying an additional 5,822 shares in the last quarter. Frazier Life Sciences Management L.P. increased its position in shares of Maze Therapeutics by 10.2% during the second quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company’s stock worth $150,182,000 after acquiring an additional 465,641 shares in the last quarter. AXQ Capital LP raised its holdings in shares of Maze Therapeutics by 114.1% during the second quarter. AXQ Capital LP now owns 15,193 shares of the company’s stock worth $453,000 after acquiring an additional 8,098 shares during the period. Braidwell LP bought a new stake in Maze Therapeutics in the 2nd quarter valued at $34,019,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Maze Therapeutics by 4,054.3% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 17,739 shares of the company’s stock valued at $529,000 after acquiring an additional 17,312 shares in the last quarter.

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically driven diseases. The company combines human genetics, functional genomics and drug discovery technologies through its Maze Compass platform to identify disease mechanisms and develop therapies designed to address the underlying causes of disease.

Maze’s lead program, MZE001, is an oral small-molecule inhibitor of glycogen synthase being developed for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles and other tissues.